Patient-specific neoantigen–Major Histocompatibility Complex on autologous peptide-pulsed dendritic cells (NeoAg-MHC-DC)

Patient-specific neoantigen–Major Histocompatibility Complex (MHC) complexes on autologous peptide-pulsed dendritic cells (DCs) represent a highly personalized therapeutic target in oncology. This approach involves identifying unique mutations within a patient's tumor via genomic sequencing and then loading (pulsing) the patient's own dendritic cells with synthetic peptides corresponding to these neoantigens (Carreno et al., 2015). These dendritic cells then present the neoantigens via MHC Class I and II molecules to naive T cells, effectively training the immune system to recognize the tumor as foreign (Hu et al., 2021). The primary biological function of this complex is to induce a potent, polyfunctional T-cell response, specifically expanding cytotoxic CD8+ T cells capable of infiltrating the tumor microenvironment and destroying malignant cells (Ott et al., 2017). Because neoantigens are absent from healthy tissues, this target offers a high degree of specificity and a favorable safety profile compared to traditional chemotherapy or non-specific immunotherapies. Current clinical applications often combine these DC-based complexes with immune checkpoint inhibitors to overcome tumor-induced immunosuppression and enhance therapeutic efficacy (Keskin et al., 2019). However, the strategy remains limited by the intensive manufacturing requirements and the potential for tumors to evolve through antigen loss or MHC downregulation.

Other names

Personalized neoantigen-pulsed dendritic cell vaccineAutologous neoantigen-loaded DC vaccineNeoantigen-MHC complexPersonalized cancer vaccine (PCV)Neoantigen-presenting dendritic cells

Activation of neoantigen-specific T-cell receptors (TCRs) through the presentation of tumor-specific mutant peptides on MHC molecules by professional antigen-presenting cells.